Chronic lymphocytic leukemia Trials in Los Angeles, United States
Conditions / Chronic lymphocytic leukemia / Los Angeles, United States
Chronic lymphocytic leukemia has been the subject of sustained clinical investigation across multiple research sites.
45 total trials for this combination
Showing top 10 of 45 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | RECRUITING | — |
| NCT03844048 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03701282 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | — |
| NCT02048813 | Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ACTIVE_NOT_RECRUITING | — |
| NCT03737981 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | — |
| NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | RECRUITING | — |
| NCT03701282 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | — |
| NCT03737981 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | — |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | TERMINATED | PHASE1 |
| NCT02048813 | Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ACTIVE_NOT_RECRUITING | — |